What's Going On With Cancer Firm Kazia Therapeutics

Core Insights - Kazia Therapeutics Limited announced a private placement of approximately $50 million in shares and prefunded warrants, priced at $5 per ADS, with each ADS representing 500 ordinary shares [1] - The net proceeds are expected to be around $46.5 million, which will be utilized for the clinical development of paxalisib, advancing the PD-L1 degrader program, and general corporate purposes [2] - The company anticipates that the net proceeds from the PIPE, along with existing cash, will extend its cash runway into the second half of 2028 [3] Clinical Developments - Kazia Therapeutics reported an initial immune-complete response in a patient with stage IV triple-negative breast cancer treated with paxalisib, pembrolizumab, and standard chemotherapy under an FDA-authorized protocol [3] - After approximately three months of treatment, a PET/CT scan indicated that all previously identified lesions had completely resolved metabolically in the same patient [4] Stock Performance and Predictions - The average 1-year price target for Kazia Therapeutics shares is $20.0, indicating an expected upside of 104.12% [5] - No analysts have bearish recommendations for Kazia Therapeutics, while one analyst has a bullish rating [6] - As of the last check, KZIA stock is up 10.49% at $10.11 [6]